Portal de Periódicos da CAPES

The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders

2017; BioMed Central; Volume: 8; Issue: 1 Linguagem: Inglês

10.1186/s13229-017-0146-8

2040-2392

Eva Loth, Tony Charman, Luke Mason, Julian Tillmann, Emily J. H. Jones, Caroline Wooldridge, Jumana Ahmad, Bonnie Auyeung, Claudia Brogna, Sara Ambrosino, Tobias Banaschewski, Simon Baron‐Cohen, Sarah Baumeister, Christian F. Beckmann, Michael Brammer, Daniel Brandeis, Sven Bölte, Thomas Bourgeron, Carsten Bours, Yvette de Bruijn, Bhismadev Chakrabarti, Daisy Crawley, Ineke Cornelissen, Flavio Dell’ Acqua, Guillaume Dumas, Sarah Durston, Christine Ecker, Jessica Faulkner, Vincent Frouin, Pilar Garcés, David Goyard, Hannah Hayward, Lindsay Ham, Joerg F. Hipp, Rosemary Holt, Mark H. Johnson, Johan Isaksson, Prantik Kundu, Meng‐Chuan Lai, Xavier Liogier D’ardhuy, Michael Lombardo, David J. Lythgoe, René C.W. Mandl, Andreas Meyer‐Lindenberg, Carolin Moessnang, Nico Mueller, Laurence O’Dwyer, Marianne Oldehinkel, Bob Oranje, Gahan Pandina, Antonio M. Persico, Amber Ruigrok, Barbara Ruggeri, Jessica Sabet, Roberto Sacco, Antonia San José Cáceres, Emily Simonoff, Roberto Toro, Heike Tost, Jack Waldman, Steven Williams, Marcel P. Zwiers, Will Spooren, Declan Murphy, Jan K. Buitelaar,

Child Development and Digital Technology

The tremendous clinical and aetiological diversity among individuals with autism spectrum disorder (ASD) has been a major obstacle to the development of new treatments, as many may only be effective in particular subgroups. Precision medicine approaches aim to overcome this challenge by combining pathophysiologically based treatments with stratification biomarkers that predict which treatment may be most beneficial for particular individuals. However, so far, we have no single validated stratification biomarker for ASD. This may be due to the fact that most research studies primarily have focused on the identification of mean case-control differences, rather than within-group variability, and included small samples that were underpowered for stratification approaches. The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD.